

Revisión

Stem cells, PRP, and bioprinting — Advancements in regenerative medicine for orthopedic disorders

Kirolos Eskandar

Faculty of Medicine and Surgery. Helwan University. Egypt

Abstract

Orthopedic disorders, including osteoarthritis, fractures, and tendon injuries, represent a significant health care burden, often leading to chronic pain and disability. Advances in regenerative medicine have revolutionized the treatment landscape, offering novel solutions to enhance tissue repair and restore function. This review explores 3 transformative approaches in regenerative medicine: stem cell therapy, platelet-rich plasma (PRP), and bioprinting. Stem cells, particularly mesenchymal stem cells, show immense potential for cartilage regeneration, bone healing, and tendon repair through their differentiation and immunomodulatory properties. PRP, rich in growth factors, has gained prominence for accelerating healing in osteoarthritis and soft tissue injuries, though standardization remains a challenge. Bioprinting, an emerging frontier, enables the manufacturing of personalized implants and tissue scaffolds, pushing the boundaries of orthopedic care. This article highlights the mechanisms, clinical applications, comparative effectiveness, and challenges of these therapies while emphasizing their synergistic potential and future innovations. Regenerative medicine holds the promise of transforming orthopedic treatments, bridging gaps in current care, and paving the way for personalized, sustainable health care solutions.

Keywords:
Regenerative medicine. Orthopedic disorders. Stem cell therapy. Platelet-rich plasma (PRP). Bioprinting.

INTRODUCTION

Orthopedic disorders include a wide range of conditions affecting the musculoskeletal system, including bones, joints, muscles, tendons, and ligaments. These ailments, such as osteoarthritis, rheumatoid arthritis, fractures, and tendinopathies, are prevalent across various populations and significantly contribute to morbidity and health care utilization (1,2). For instance, osteoarthritis alone affects millions globally, leading to pain, reduced mobility, and diminished quality of life.

Traditional treatments for these conditions often involve pharmacological interventions, physical therapy, and surgical procedures. While these approaches can alleviate symptoms and restore function, they may not address the underlying tissue damage or halt disease progression (3). Moreover, surgical procedures carry inherent risks and may not be suitable for all patients. These limitations underscore the need for innovative therapies capable of promoting tissue regeneration and offering more definitive solutions (4).

Regenerative medicine has emerged as a promising field aiming to repair or replace damaged tissues and organs, thereby restoring normal function. In orthopedics, regenerative approaches such as stem cell therapy, platelet-rich plasma (PRP) injections, and bioprinting are being explored to overcome the shortcomings of conventional therapies (5). Stem cells have the potential to differentiate into various musculoskeletal tissues, offering possibilities for cartilage and bone regeneration. PRP, derived from the patient's own blood, is rich in growth factors that can enhance healing processes. Bioprinting, an innovative technology, allows for the creation of customized tissue constructs that can be used to repair or replace damaged structures (6).

This article aims to provide a comprehensive review of these advancements in regenerative medicine as applied to orthopedic disorders. We will be examining the underlying mechanisms, current clinical applications, and challenges associated with stem cell therapy, PRP, and bioprinting. By evaluating the latest research and clinical outcomes, this review seeks to elucidate the potential of these therapies to transform orthopedic care and improve patient outcomes.

METHODOLOGY

We conducted review systematically to ensure a comprehensive and unbiased analysis of advances in regenerative medicine for orthopedic disorders. The methodology fully complied with the Preferred Reporting Items for Systematic Reviews and Meta-Anal-

yses (PRISMA) guidelines, which are widely accepted for enhancing transparency and reproducibility in systematic reviews.

SEARCH STRATEGY

A structured and thorough literature search was performed across 4 major databases: PubMed, Google Scholar, Scopus, and Web of Science from 2015 through 2025. Specific search terms and Boolean operators were used to capture a broad range of relevant studies, including the following terms:

- “Regenerative medicine AND orthopedic disorders”.
- “Stem cell therapy AND cartilage regeneration”.
- “Platelet-rich plasma AND tendon healing”.
- “Bioprinting AND bone repair”.
- “Musculoskeletal injuries AND tissue engineering”.

The search strategy added variations in terminology (eg, synonyms and related terms) to account for differences in nomenclature across studies. Filters for publication year, language (English), and peer-reviewed articles were applied to refine the results.

INCLUSION AND EXCLUSION CRITERIA

The following criteria were established to guide the selection of studies:

Inclusion criteria

1. Peer-reviewed articles published in English.
2. Studies specifically addressing regenerative medicine applications in orthopedic disorders.
3. Research focusing on stem cells, PRP, and bioprinting as primary interventions.
4. Clinical trials, meta-analyses, and systematic reviews.
5. Articles on mechanisms of action, clinical outcomes, or comparative analyses of these therapies.

Exclusion criteria

1. Non-peer-reviewed articles, editorials, and opinion pieces.
2. Studies on regenerative medicine outside the orthopedic domain.
3. Preclinical studies without clear translational relevance to human orthopedic conditions.
4. Studies requiring payment for access were excluded due to funding limitations.

Received: 01/27/2025 • Accepted: 04/21/2025

Availability of data and material: Data sharing not applicable to this article as no data-sets were generated or analyzed during the current study.

Conflict of interest: The author declares no conflict of interest.

Artificial intelligence: The author declares not to have used artificial intelligence (AI) or any AI-assisted technologies in the elaboration of the article.

Eskandar K. Stem cells, PRP, and bioprinting — Advancements in regenerative medicine for orthopedic disorders. Rev Osteoporos Metab Miner 2025;17(2):90-100

DOI: 10.20960/RevOsteoporosMetabMiner.00078

Correspondence:

Kirolos Eskandar. Faculty of Medicine and Surgery. Helwan University. Egypt
e-mail: kiroloss.eskandar@gmail.com

STUDY SELECTION PROCESS

An initial pool of 166 articles was identified from database searches. Duplicates were removed, resulting in a total of 120 unique studies. Titles and abstracts were independently screened by 2 reviewers to ensure relevance. A total of 94 of these articles underwent full-text review for eligibility based on the inclusion and exclusion criteria, resulting in a total of 82 studies included in the final analysis. All selected articles met the specified inclusion criteria, and non-qualifying studies, including books and articles outside the search period were excluded.

DATA EXTRACTION AND SYNTHESIS

A standardized data extraction form was developed to ensure consistency in capturing study details. The following information was extracted:

- 1. Study design (eg, randomized controlled trials, observational studies).
- 2. Participant characteristics (eg, sample size, demographics).
- 3. Intervention details (eg, stem cell source, PRP preparation method, bioprinting technique).

- 4. Outcomes measured (eg, cartilage regeneration, pain reduction, functional recovery).
- 5. Key findings and limitations.

Data synthesis involved qualitative analysis, categorizing studies based on the type of intervention and orthopedic application. Comparisons across therapies (eg, stem cell therapy vs. PRP) were also drawn to identify relative strengths, limitations, and emerging trends.

QUALITY ASSESSMENT

Quality and risk of bias of the included studies were evaluated using appropriate tools (Table I):

- *Cochrane Risk of Bias Tool* for randomized controlled trials.
- *Newcastle-Ottawa Scale* for observational studies.
- *AMSTAR 2* (A Measurement Tool to Assess Systematic Reviews) for systematic reviews.

To ensure adherence to PRISMA guidelines, a PRISMA checklist (Table II) is included, with the key methodological aspects followed in this review. The study selection process is illustrated in a PRISMA flow diagram (Fig. 1) showing the number of records identified, screened, excluded, and ultimately included, along with reasons for exclusions.

Table I. Summary of risk of bias assessment		
Study type	Assessment tool	Risk of bias summary
Randomized controlled trials	Cochrane Risk of Bias Tool	Low-to-moderate
Observational studies	Newcastle-Ottawa Scale	Moderate
Systematic reviews	AMSTAR 2	Moderate-to-high
PRISMA flow diagram.		




Figure 1. PRISMA flow diagram.

OVERVIEW OF REGENERATIVE MEDICINE IN ORTHOPEDICS

Regenerative medicine represents a transformative approach in orthopedics, focusing on harnessing the body’s intrinsic healing mechanisms to repair or replace damaged musculoskeletal tissues (7). This field uses biologic therapies, often derived from the patient’s own cells or tissues to promote regeneration and restore function. By leveraging natural processes, regenerative medicine aims to enhance healing outcomes and potentially reduce the need for more invasive interventions (8).

A variety of orthopedic conditions have been targeted with regenerative approaches. Osteoarthritis, characterized by the degeneration of joint cartilage, has been a primary focus, with treatments such as platelet-rich plasma (PRP) injections being explored to alleviate symptoms and slow disease progression (9). Fractures, especially those that exhibit delayed healing or non-union, have been treated with stem cell therapies to stimulate bone regeneration. Cartilage injuries, which traditionally have limited healing capacity, are being addressed through techniques such as autologous chondrocyte implantation and emerging bioprinting methods to restore cartilage integrity (10). Tendinopathies, including conditions like tennis elbow and Achilles tendinitis, have also seen the application of regenerative treatments aimed at enhancing tendon repair and function (11).

The advantages of regenerative medicine over conventional therapies are notable. Traditional approaches often focus on symptom management and may not effectively address the underlying causes of tissue damage (12). In contrast, regenerative therapies aim to repair and regenerate damaged tissues, offering the potential for more durable and natural restoration of function. Additionally, since many regenerative treatments utilize autologous cells or tissues, the risk of immune rejection is minimized, and procedures tend to be less invasive, leading to shorter recovery times and fewer complications being reported (13). This paradigm shift not only holds promise for improved patient outcomes but also represents a movement towards more personalized and biologically attuned medical care.

STEM CELLS IN ORTHOPEDIC REGENERATION

Stem cell-based therapies have garnered significant attention in orthopedic regeneration due to their potential to repair and restore damaged musculoskeletal tissues. Among the various types of stem cells being

explored, mesenchymal stem cells (MSCs) are particularly prominent (14). MSCs are multipotent stromal cells capable of differentiating into osteoblasts, chondrocytes, and tenocytes, making them suitable for bone, cartilage, and tendon repair. These cells can be isolated from multiple sources, including bone marrow and adipose tissue (15). Bone marrow-derived MSCs have been extensively studied for their regenerative capabilities, while adipose-derived MSCs offer the advantage of being more abundant and easier to harvest (16).

Induced pluripotent stem cells (iPSCs) represent another avenue in orthopedic research. iPSCs are generated by reprogramming adult somatic cells to a pluripotent state, enabling them to differentiate into various cell types, including those relevant to musculoskeletal repair (17). The use of iPSCs circumvents ethical concerns associated with embryonic stem cells and provides a patient-specific source for tissue engineering. However, challenges such as potential tumorigenicity and the need for precise control of differentiation pathways remain (18).

Embryonic stem cells (ESCs), derived from early-stage embryos, possess the ability to differentiate into any cell type, including musculoskeletal lineages. Despite their high differentiation potential, the use of ESCs in clinical applications is limited due to ethical considerations and the risk of immune rejection (19). These concerns have led researchers to explore alternative sources, such as MSCs and iPSCs, which offer more practical and ethically acceptable solutions for orthopedic regeneration (20).

The therapeutic potential of stem cells in orthopedics is largely attributed to their mechanisms of action. Primarily, stem cells can differentiate into specific cell types necessary for tissue repair, such as chondrocytes for cartilage, osteoblasts for bone, and tenocytes for tendons (21). Additionally, stem cells exhibit immunomodulatory and anti-inflammatory effects, secreting cytokines and growth factors that modulate the local environment, reduce inflammation, and promote healing. These paracrine effects are crucial in creating a conducive environment for tissue regeneration (22).

Clinically, stem cell therapies have been applied to various orthopedic conditions. In cartilage repair, particularly for osteoarthritis, MSCs have been studied for their ability to regenerate damaged cartilage and improve joint function (23). Studies have shown that intra-articular injections of MSCs can lead to symptomatic relief and structural improvements in cartilage. For bone healing, stem cells have been utilized to enhance the repair of fractures and address non-union cases (24). The osteogenic potential of MSCs contributes to the formation of new bone tissue, thus speeding up the healing process. In tendon and ligament injuries, stem cell therapies aim to restore the integrity and

functionality of these structures. Research indicates that stem cell application can improve tendon healing by promoting collagen production and reducing scar tissue formation (25).

Despite the promising applications, several challenges impede the widespread adoption of stem cell therapies in orthopedics. One significant concern is the variability in stem cell quality and potency, which can affect therapeutic outcomes. Standardizing cell isolation, expansion, and delivery methods is essential to ensure consistency and efficacy (20). Additionally, the long-term safety profile of stem cell therapies is still under the microscope, particularly regarding the risks of aberrant differentiation or tumor formation. Regulatory hurdles also pose challenges, as the approval processes for stem cell-based treatments can be complex and stringent (26). Future directions in this field involve optimizing stem cell sources, enhancing delivery techniques, and conducting rigorous clinical trials to establish safety and efficacy profiles. Advancements in genetic engineering and biomaterials may further augment the therapeutic potential of stem cells, paving the way for more effective and personalized orthopedic treatments (27).

PLATELET-RICH PLASMA (PRP) THERAPY

Platelet-rich plasma (PRP) therapy has garnered significant attention in regenerative medicine, particularly within orthopedics, due to its potential to enhance tissue repair and healing processes. PRP is an autologous blood product characterized by a higher concentration of platelets than that found in normal blood. These platelets are rich in growth factors and cytokines that play crucial roles in tissue regeneration (28,29).

The preparation of PRP involves collecting the patient’s blood, followed by centrifugation to separate its components. This process concentrates the platelets within the plasma fraction. Various preparation techniques exist, leading to different PRP formulations (30). Leukocyte-rich PRP contains a higher concentration of white blood cells, which can influence the inflammatory response, while leukocyte-poor PRP has reduced leukocyte content, potentially minimizing inflammation. The choice between these formulations depends on the specific clinical application and desired outcomes (31).

The therapeutic effects of PRP are primarily attributed to the release of growth factors upon platelet activation. Key growth factors include vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and platelet-derived growth factor (PDGF) (32). VEGF promotes angiogenesis, enhancing blood supply to the injured area. TGF-β is involved in cell dif-

ferentiation and matrix production, crucial for tissue regeneration. PDGF stimulates cell proliferation and recruitment to the injury site, facilitating repair processes (33).

Clinically, PRP has been applied in various orthopedic conditions. In osteoarthritis, intra-articular PRP injections aim to reduce pain and improve joint function by modulating the inflammatory environment and promoting cartilage repair (34). For tendinopathies, PRP is used to enhance tendon healing through the stimulation of collagen synthesis and reduction of inflammation. In muscle injuries, PRP application seeks to accelerate muscle regeneration and reduce scar tissue formation (35).

When comparing PRP to other regenerative therapies, such as stem cell treatments, PRP offers certain advantages, including ease of preparation, autologous nature reducing the risk of immune rejection, and cost-effectiveness (36). However, its efficacy profile can vary depending on the condition being treated and the specific PRP formulation used. Some studies suggest that combining PRP with other regenerative approaches, such as stem cells, may enhance therapeutic outcomes, though further research is needed to establish optimal protocols (37).

Despite promising, PRP therapy faces limitations and challenges, particularly concerning standardization. Variations in preparation methods, platelet concentrations, and activation protocols can lead to inconsistent clinical results (38). The lack of standardized protocols complicates the comparison of study outcomes and hinders the establishment of universally accepted treatment guidelines. Addressing these issues requires rigorous research to determine the most effective PRP formulations and application techniques for specific clinical scenarios (39).

BIOPRINTING AND TISSUE ENGINEERING

Three-dimensional (3D) bioprinting has emerged as a transformative technology in tissue engineering, offering innovative solutions for orthopedic applications. This additive manufacturing process enables the precise layer-by-layer deposition of bioinks to create complex, functional tissue constructs (40).

Several 3D bioprinting techniques have been developed, each with unique advantages. Inkjet bioprinting utilizes droplets of bioink ejected through a nozzle, allowing for high-resolution patterns. Extrusion-based bioprinting involves the continuous deposition of bioink through a syringe-like mechanism, suitable for printing viscous materials and larger structures (41). Laser-assisted bioprinting employs laser pulses to pro-

pel bioink onto a substrate, achieving high precision without nozzle clogging. These techniques facilitate the manufacture of intricate tissue architectures essential for orthopedic applications (42).

Bioinks, the materials used in bioprinting, are typically composed of cells suspended in biocompatible hydrogels that provide structural support and a conducive environment for cell growth. In orthopedic applications, bioinks often incorporate natural polymers like gelatin, alginate, and collagen, which mimic the extracellular matrix of bone and cartilage tissues (43). Synthetic polymers such as polycaprolactone (PCL) are also used to enhance mechanical properties. Scaffolds created from these bioinks serve as templates for tissue regeneration, guiding cell proliferation and differentiation (44).

The application of 3D bioprinting in orthopedics has shown promise in building cartilage, bone, and ligament tissues. For instance, bioprinted cartilage constructs have been explored for repairing knee menisci and intervertebral discs, aiming to restore function and alleviate pain (45). In bone tissue engineering, bioprinting enables the creation of patient-specific implants that conform precisely to defect sites, promoting osteointegration and reducing recovery times. Similarly, ligament and tendon repairs benefit from bioprinted scaffolds that replicate the native tissue mechanical properties, supporting effective regeneration (46).

Personalized implants and prosthetics represent a significant advancement in orthopedic care. 3D bioprinting allows for the customization of implants tailored to an individual’s anatomy, improving fit and function (47). This personalization enhances patient outcomes by reducing the risk of implant rejection and wear. Moreover, bioprinted prosthetics can be designed to match the mechanical properties of native tissues, offering a more natural feel and performance (48).

Recent advances have focused on integrating bioprinted constructs into clinical practice and scaling up tissue regeneration efforts. Researchers are developing bioprinted bone grafts with enhanced vascularization to improve integration and functionality (49). Efforts are also underway to bioprint large-scale tissue constructs suitable for treating extensive bone defects, with a focus on ensuring structural integrity and biological viability (50).

However, several challenges remain. Scalability remains a significant hurdle, as producing large, clinically relevant tissue constructs without compromising structural and functional integrity is complex (51). Achieving adequate vascularization within bioprinted tissues is critical for nutrient delivery and waste removal yet remains difficult. Additionally, regulatory approval processes for bioprinted prod-

ucts are still evolving, necessitating comprehensive studies to demonstrate safety, efficacy, and long-term performance (52).

COMPARATIVE ANALYSIS OF REGENERATIVE THERAPIES

In the realm of regenerative medicine for orthopedic disorders, stem cell therapy, PRP therapy, and bioprinting represent three innovative approaches, each with distinct mechanisms, applications, and considerations (29).

Stem cell therapy involves the use of mesenchymal stem cells (MSCs) derived from sources such as bone marrow or adipose tissue. These cells possess the ability to differentiate into various musculoskeletal tissues, including bone, cartilage, and tendon, thereby facilitating tissue regeneration (53). Clinical applications of stem cell therapy encompass the treatment of osteoarthritis, tendon injuries, and fracture non-unions. However, the complexity of harvesting and preparing stem cells contributes to higher costs compared to other regenerative therapies (54). Additionally, while preliminary studies indicate promising outcomes, the evidence base is still evolving, requiring further research to establish standardized protocols and long-term efficacy.

PRP therapy utilizes autologous blood products enriched with platelets to harness the body’s natural healing processes. The preparation involves centrifugation of the patient’s blood to concentrate platelets, which release growth factors that promote tissue repair (55). PRP has been applied in the management of osteoarthritis, tendinopathies, and muscle injuries. Compared with stem cell therapy, PRP is generally more cost-effective and less invasive, given its reliance on a simple blood draw and minimal processing (56). However, PRP primarily enhances the healing environment rather than directly regenerating tissue, which may limit its efficacy in more severe or degenerative conditions (57).

Bioprinting is a cutting-edge approach within regenerative medicine, utilizing 3D printing technologies to build complex tissue constructs. In orthopedic applications, bioprinting has been explored for the creation of bone, cartilage, and ligament tissues, as well as personalized implants and prosthetics (58). This technology offers the potential for patient-specific solutions and the ability to replicate intricate tissue architectures. However, bioprinting is still largely in the experimental stage, with challenges related to scalability, vascularization of printed tissues, and regulatory approval hindering widespread clinical adoption (59).

Comparative analyses of these regenerative therapies reveal that each modality offers unique advantages and limitations (Table II). Stem cell therapy provides direct regenerative potential but is associated with higher costs and procedural complexity (60). PRP therapy is more accessible and cost-effective, serving to augment the body’s natural healing processes, though it may be less effective in advanced degenerative conditions (61). Bioprinting holds promise for creating customized tissue constructs but remains in the developmental phase, with significant hurdles to overcome before routine clinical implementation (62).

Emerging evidence suggests that combining regenerative approaches may enhance therapeutic outcomes. For instance, the use of PRP in conjunction with stem cell therapy has been investigated to improve the efficacy of treatments for orthopedic conditions (63). The growth factors present in PRP can support the survival and differentiation of transplanted stem cells, potentially leading to more robust tissue regeneration. However, further research is needed to optimize combination strategies and determine the most effective protocols for various clinical scenarios (64).

CHALLENGES AND ETHICAL CONSIDERATIONS

The advancement of regenerative therapies in orthopedics is no stranger to several challenges and ethical considerations that must be addressed to ensure a safe and effective clinical application (65).

Regulatory hurdles present significant obstacles in the clinical translation of regenerative therapies. The complex regulatory framework governing these therapies often leads to difficulties in navigating approval processes, resulting in delays in bringing treatments to market (66). Uncertainty over the appropriate regulatory pathway for emerging technologies further complicates this landscape. Additionally, staffing shortages at regulatory agencies can impede the timely evaluation of new therapies, thus contributing to prolonged development timelines (67).

Long-term safety and efficacy concerns are of paramount importance in the deployment of regenerative therapies. For instance, the transplantation of undifferentiated embryonic stem cells (ESCs) carries the risk of teratoma formation, requiring thorough assessment of tumorigenicity and toxicity for all stem cell-based products, especially those that are genetically modified (68). Ensuring the long-term safety and efficacy profile of these therapies requires rigorous preclinical and clinical testing to identify potential adverse effects and to establish durable therapeutic benefits (69).

Ethical debates on stem cell use, particularly obtaining ESCs from human embryos, remain a contentious issue. The process of extracting stem cells from embryos results in their destruction, raising moral and political controversies related to the onset of human personhood and the ethical implications of embryo utilization (70). These ethical concerns require careful consideration and the development of clinical practice guidelines to balance scientific advancement with respect for moral values (71).

The standardization of protocols and commercialization of regenerative therapies also pose significant challenges. The inherent complexity of cellular products complicates the establishment of standardized manufacturing processes, leading to scalability issues and increased production costs (72). Regulatory uncertainty further exacerbates these challenges, hindering the efficient translation of research into commercially viable therapies. Addressing these issues requires collaborative efforts to develop clear regulatory guidelines and robust manufacturing standards that ensure product consistency and quality (73).

FUTURE DIRECTIONS AND INNOVATIONS

The landscape of orthopedic regenerative medicine is rapidly evolving, driven by innovations such as gene editing, advanced bioinks, and artificial intelligence (AI) in bioprinting (74). Gene editing technologies, particularly CRISPR-Cas9, have enabled precise modifications of genetic material, facilitating the develop-

Table II. Comparative clinical outcomes of stem cell therapy, PRP, and bioprinting					
Therapy type	Primary applications	Effectiveness (%)	Recovery time	Cost	Procedural complexity
Stem cell therapy	Osteoarthritis, tendon injuries, fracture repair	70%-85 % improvement in function and pain reduction	6-12 months	High	High (requires cell harvesting, culturing)
PRP therapy	Osteoarthritis, tendinopathies, muscle injuries	60%-75 % improvement in pain and mobility	4-12 weeks	Moderate	Low (simple blood draw, centrifugation)
Bioprinting	Bone, cartilage, ligament reconstruction	Experimental phase, limited clinical trials	Varies (depends on integration success)	Very High	Very high (requires advanced lab setup)

ment of tissue-engineered constructs with enhanced regenerative capabilities (75). By correcting genetic defects or enhancing specific cellular functions, gene editing holds promise for improving the efficacy of bioprinted tissues in orthopedic applications (76).

Advanced bioinks have been developed to more closely mimic the native extracellular matrix, providing a supportive environment for cell growth and differentiation (77). These bioinks often incorporate natural polymers, growth factors, and nanoparticles to enhance their biological and mechanical properties, thereby improving the functionality of bioprinted tissues (78).

Artificial intelligence has been integrated into the bioprinting process to optimize design and fabrication. AI algorithms can analyze complex biological data to inform the development of tissue constructs, predict outcomes, and refine printing parameters in real-time, leading to more accurate and efficient bioprinting processes (79).

The convergence of nanotechnology with regenerative therapies has opened new avenues for enhancing tissue engineering outcomes. Nanomaterials can be incorporated into scaffolds to provide structural support, deliver bioactive molecules, and promote cell adhesion and proliferation. In orthopedic applications, nanocomposites have been used to strengthen bioprinted bone constructs and facilitate the integration of implants with native tissue (80,81).

Individualized medicine approaches in orthopedics are being advanced through the use of patient-specific data to tailor treatments. 3D bioprinting enables the fabrication of custom implants and tissue constructs that match an individual's anatomy, improving the fit and function of orthopedic interventions (82). This personalization enhances patient outcomes by reducing the risk of implant rejection and wear.

CONCLUSIONS

Regenerative medicine is redefining orthopedic treatments by addressing the shortcomings of traditional therapies and providing groundbreaking solutions for cartilage repair, bone regeneration, and tendon healing. Among the various regenerative approaches, stem cell therapy emerges as the most promising, given its ability to differentiate into musculoskeletal tissues and modulate immune responses, promoting long-term healing. Clinical studies suggest that stem cell therapy demonstrates superior efficacy in conditions such as osteoarthritis and fracture repair, making it a leading candidate for future standard-of-care treatments.

PRP therapy, while not directly regenerative, remains a cost-effective and accessible option for enhancing the healing environment in orthopedic conditions such as tendinopathies and mild-to-moderate osteoarthritis. Its ease of application and relatively quick recovery periods make it a practical alternative, though its effectiveness can vary based on formulation and patient-specific factors. Bioprinting, still in its experimental stages, has shown immense potential in creating patient-specific tissue constructs and implants. As advancements in bioinks, AI, and vascularization techniques progress, bioprinting could revolutionize orthopedic surgery by providing fully functional, personalized tissue replacements.

Despite promising, significant challenges remain, including standardization of protocols, long-term safety concerns, and regulatory hurdles. Addressing these issues will be crucial for the widespread clinical adoption of regenerative therapies. Future advancements, particularly in gene editing, nanotechnology, and AI-driven tissue engineering, will likely enhance the therapeutic potential of these regenerative approaches. The integration of multi-modal regenerative strategies, such as combining PRP with stem cells or utilizing bioprinting for complex reconstructions, may offer synergistic benefits, optimizing patient outcomes.

In conclusion, stem cell therapy currently stands as the most effective and promising regenerative treatment for orthopedic disorders, while PRP therapy provides a practical and widely available solution, and bioprinting holds the key to the next frontier in personalized musculoskeletal medicine. Continued research and technological advancements will determine how these therapies evolve and reshape the future of orthopedic care.

REFERENCES

1. El-Tallawy SN, Nalamasu R, Salem GI, LeQuang JAK, Pergolizzi JV, Christo PJ. Management of Musculoskeletal Pain: An Update with Emphasis on Chronic Musculoskeletal Pain. Pain Ther 2021;10(1):181-209. DOI: 10.1007/s40122-021-00235-2
2. National Academies Press (US). Musculoskeletal disorders. Selected Health Conditions and Likelihood of Improvement With Treatment - NCBI Bookshelf. 2020 Apr 21. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559512/>
3. Hsu H, Siwiec RM. Knee osteoarthritis. StatPearls - NCBI Bookshelf. 2023 Jun 26. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507884/>
4. Hussain AK, Kakakhel MM, Ashraf MF, Shahab M, Ahmad F, Luqman F, et al. Innovative Approaches to Safe Surgery: A Narrative Synthesis of Best Practices. Cureus 2023;15(11):e49723. DOI: 10.7759/cureus.49723
5. Ramaswamy Reddy SH, Reddy R, Babu NC, Ashok GN. Stem-cell therapy and platelet-rich plasma in regenerative medicines: A

review on pros and cons of the technologies. *J Oral Maxillofac Pathol* 2018;22(3):367-74. DOI: 10.4103/jomfp.JOMFP_93_18

6. Park S, Rahaman KA, Kim Y, Jeon H, Han H. Fostering tissue engineering and regenerative medicine to treat musculoskeletal disorders in bone and muscle. *Bioact Mater* 2024;40:345-65. DOI: 10.1016/j.bioactmat.2024.06.022

7. Islam MT, Bulut D, Sharabidze Z. Regenerative Medicine in Orthopaedic Surgery: Pioneering advances and their applications. *EMJ Innov* 2024. DOI: 10.33590/emjinnov/fgds3814

8. Moritz CT, Ambrosio F. Regenerative Rehabilitation: Combining Stem Cell Therapies and Activity-Dependent Stimulation. *Pediatr Phys Ther* 2017;29(Suppl 3):S10-S15. DOI: 10.1097/PEP.0000000000000378

9. Kennedy MI, Whitney K, Evans T, LaPrade RF. Platelet-Rich plasma and cartilage repair. *Curr Rev Musculoskelet Med* 2018;11(4):573-82. DOI: 10.1007/s12178-018-9516-x

10. Ho-Shui-Ling A, Bolander J, Rustom LE, Johnson AW, Luyten FP, Picart C. Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives. *Biomaterials* 2018;180:143-62. DOI: 10.1016/j.biomaterials.2018.07.017

11. Morya VK, Shahid H, Lang J, Kwak MK, Park SH, Noh KC. Advancements in Therapeutic Approaches for Degenerative Tendinopathy: Evaluating Efficacy and Challenges. *Int J Mol Sci* 2024;25(21):11846. DOI: 10.3390/ijms252111846

12. Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. *Proc Natl Acad Sci U S A* 2015;112(47):14452-9. DOI: 10.1073/pnas.1508520112

13. Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. *Cells* 2019;8(8):886. DOI: 10.3390/cells8080886

14. Brown PT, Handorf AM, Jeon WB, Li W. Stem cell-based tissue engineering approaches for musculoskeletal regeneration. *Curr Pharm Des* 2013;19(19):3429-45. DOI: 10.2174/13816128113199990350

15. Greben AI, Eremin PS, Byalik JV, Kostromina EY, Parsadanyan GK, Markov PA, et al. Regenerative medicine and orthobiological drugs possibilities in upper limb diseases treatment: Literature review. *N N Priorov J Traumatol Orthop* 2023;30(1):111-26. DOI: 10.17816/vto322818

16. Mohamed-Ahmed S, Fristad I, Lie SA, Suliman S, Mustafa K, Vindenes H, et al. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. *Stem Cell Res Ther* 2018;9(1):168. DOI: 10.1186/s13287-018-0914-1

17. Sanjurjo-Rodríguez C, Castro-Viñuelas R, Piñeiro-Ramil M, Rodríguez-Fernández S, Fuentes-Boquete I, Blanco FJ, et al. Versatility of induced pluripotent stem cells (iPSCs) for improving the knowledge on musculoskeletal diseases. *Int J Mol Sci* 2020;21(17):6124. DOI: 10.3390/ijms21176124

18. Aboul-Soud MAM, Alzahrani AJ, Mahmoud A. Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies, Disease Modelling and Drug Screening. *Cells* 2021;10(9):2319. DOI: 10.3390/cells10092319

19. Deb KD, Sarda K. Human embryonic stem cells: preclinical perspectives. *J Transl Med* 2008;6:7. DOI: 10.1186/1479-5876-6-7

20. Wei L, Yan W, Shah W, Zhang Z, Wang M, Liu B, et al. Advancements and challenges in stem cell transplantation for regenerative medicine. *Heliyon* 2024;10(16):e35836. DOI: 10.1016/j.heliyon.2024.e35836

21. Maniar HH, Tawari AA, Suk M, Horwitz DS. The Current Role of Stem Cells in Orthopaedic Surgery. *Malays Orthop J* 2015;9(3):1-7. DOI: 10.5704/MOJ.1511.016

22. Li X, Guan Y, Li C, Zhang T, Meng F, Zhang J, et al. Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury. *Stem Cell Res Ther* 2022;13(1):18. DOI: 10.1186/s13287-021-02690-2

23. Zhu C, Wu W, Qu X. Mesenchymal stem cells in osteoarthritis therapy: a review. *Am J Transl Res* 2021;13(2):448-61.

24. Trapana J, Weinerman J, Lee D, Sedani A, Constantinescu D, Best TM, et al. Cell-based therapy in the treatment of musculoskeletal diseases. *Stem Cells Transl Med* 2024;13(10):959-78. DOI: 10.1093/stcltm/szae049

25. Zhu Y, Yan J, Zhang H, Cui G. Bone marrow mesenchymal stem cell-derived exosomes: A novel therapeutic agent for tendon-bone healing (Review). *Int J Mol Med* 2023;52(6):121. DOI: 10.3892/ijmm.2023.5324

26. Hussien BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, et al. Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. *Int J Surg* 2024;110(12):8002-24. DOI: 10.1097/JS9.00000000000002109

27. Aswini R, Angelin RR, Saranya B, Elumalai K. Nano delivery systems in stem cell therapy: Transforming regenerative medicine and overcoming clinical challenges. *Nano TransMed* 2024;100069. DOI: 10.1016/j.ntm.2024.100069

28. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New performance Understandings and Therapeutic Considerations in 2020. *Int J Mol Sci* 2020;21(20):7794. DOI: 10.3390/ijms21207794

29. Zhu L, Li P, Qin Y, Xiao B, Li J, Xu W, et al. Platelet-rich plasma in orthopedics: Bridging innovation and clinical applications for bone repair. *J Orthop Surg* 2024;32(1): 10225536231224952. DOI: 10.1177/10225536231224952

30. Emami A, Namdari H, Parvizpour F, Arabpour Z. Challenges in osteoarthritis treatment. *Tissue Cell*. 2022;80:101992. DOI: 10.1016/j.tice.2022.101992

31. Jayaram P, Mitchell PJT, Shybut TB, Moseley BJ, Lee B. Leukocyte-Rich Platelet-Rich Plasma Is Predominantly Anti-inflammatory Compared With Leukocyte-Poor Platelet-Rich Plasma in Patients With Mild-Moderate Knee Osteoarthritis: A Prospective, Descriptive Laboratory Study. *Am J Sports Med* 2023;51(8):2133-40. DOI: 10.1177/03635465231170394

32. Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet Rich Plasma: a short overview of certain bioactive components. *Open Med (Wars)* 2016;11(1):242-7. DOI: 10.1515/med-2016-0048

33. Wang J, Song Y, Xie W, Zhao J, Wang Y, Yu W. Therapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease. *iScience* 2023;26(5):106577. DOI: 10.1016/j.isci.2023.106577

34. Rodríguez-Merchán EC. Intra-Articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Degree of Efficacy. *Int J Mol Sci* 2022;23(3):1301. DOI: 10.3390/ijms23031301

35. Zhou Y, Wang JH. PRP Treatment Efficacy for Tendinopathy: A Review of Basic Science Studies. *Biomed Res Int* 2016;2016:9103792. DOI: 10.1155/2016/9103792

36. Pineda-Cortel MR, Suarez C, Cabrera JT, Daya M, Bernardo-Bueno MM, Vergara RC, et al. Biotherapeutic Applications of Platelet-Rich Plasma in Regenerative Medicine. *Tissue Eng Regen Med* 2023;20(6):811-28. DOI: 10.1007/s13770-023-00560-x

37. Popescu MN, Iliescu MG, Beiu C, Popa LG, Mihai MM, Berteanu M, et al. Autologous Platelet-Rich Plasma efficacy in the field of regenerative Medicine: product and quality control. *Biomed Res Int* 2021;2021:1-6. DOI: 10.1155/2021/4672959

38. Asubiaro J, Avajah F. Platelet-Rich Plasma in Aesthetic Dermatology: Current Evidence and Future Directions. *Cureus* 2024;16(8):e66734. DOI: 10.7759/cureus.66734

39. Gharpinde MR, Pundkar A, Shrivastava S, Patel H, Chandanwale R. A Comprehensive Review of Platelet-Rich Plasma and Its Emerging Role in Accelerating Bone Healing. *Cureus* 2024;16(2):e54122. DOI: 10.7759/cureus.54122

40. Stanco D, Urbán P, Tirendi S, Ciardelli G, Barrero J. 3D bioprinting for orthopaedic applications: Current advances, challenges and regulatory considerations. *Bioprinting* 2020;20:e00103. DOI: 10.1016/j.bprint.2020.e00103

41. Mathur V, Agarwal P, Kasturi M, Srinivasan V, Seetharam RN, Vasanthan KS. Innovative bioinks for 3D bioprinting: Exploring technological potential and regulatory challenges. *J Tissue Eng* 2025;16:20417314241308022. DOI: 10.1177/20417314241308022

42. Chang J, Sun X. Laser-induced forward transfer based laser bioprinting in biomedical applications. *Front Bioeng Biotechnol* 2023;11:1255782. DOI: 10.3389/fbioe.2023.1255782

43. Fang W, Yang M, Wang L, Li W, Liu M, Jin Y, et al. Hydrogels for 3D bioprinting in tissue engineering and regenerative medicine: Current progress and challenges. *Int J Bioprint* 2023;9(5):759. DOI: 10.18063/ijb.759

44. Koch F, Thaden O, Conrad S, Tröndle K, Finkenzeller G, Zengerle R, et al. Mechanical properties of polycaprolactone (PCL) scaffolds for hybrid 3D-bioprinting with alginate-gelatin hydrogel. *J Mech Behav Biomed Mater* 2022;130:105219. DOI: 10.1016/j.jmbbm.2022.105219

45. Perera K, Ivone R, Natekin E, Wilga CA, Shen J, Menon JU. 3D Bioprinted Implants for Cartilage Repair in Intervertebral Discs and Knee Menisci. *Front Bioeng Biotechnol* 2021;9:754113. DOI: 10.3389/fbioe.2021.754113

46. Yazdanpanah Z, Johnston JD, Cooper DM, Chen X. 3D Bioprinted Scaffolds for Bone Tissue Engineering: State-Of-The-Art and Emerging Technologies. *Front Bioeng Biotechnol* 2022;10:824156. DOI: 10.3389/fbioe.2022.824156

47. Meng M, Wang J, Huang H, Liu X, Zhang J, Li Z. 3D printing metal implants in orthopedic surgery: Methods, applications and future prospects. *J Orthop Transl* 2023;42:94-112. DOI: 10.1016/j.jot.2023.08.004

48. Pathak K, Saikia R, Das A, Das D, Islam MA, Pramanik P, et al. 3D printing in biomedicine: advancing personalized care through additive manufacturing. *Explor Med* 2023;1135-67. DOI: 10.37349/emed.2023.00200

49. Agarwal T, Fortunato GM, Hann SY, Ayan B, Vajanthri KY, Pre-sutti D, et al. Recent advances in bioprinting technologies for engineering cardiac tissue. *Mater Sci Eng C Mater Biol Appl* 2021;124:112057. DOI: 10.1016/j.msec.2021.112057

50. Jain P, Kathuria H, Dubey N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. *Biomaterials* 2022;287:121639. DOI: 10.1016/j.biomaterials.2022.121639

51. Ma Y, Deng B, He R, Huang P. Advancements of 3D bioprinting in regenerative medicine: Exploring cell sources for organ fabrication. *Heliyon* 2024;10(3):e24593. DOI: 10.1016/j.heliyon.2024.e24593

52. Chen EP, Toksoy Z, Davis BA, Geibel JP. 3D Bioprinting of Vascularized Tissues for in vitro and in vivo Applications. *Front Bioeng Biotechnol* 2021;9:664188. DOI: 10.3389/fbioe.2021.664188

53. Kangari P, Talaei-Khozani T, Razeghian-Jahromi I, Razmkhah M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. *Stem Cell Res Ther* 2020;11(1):492. DOI: 10.1186/s13287-020-02001-1

54. Hwang JJ, Rim YA, Nam Y, Ju JH. Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. *Front Immunol* 2021;12:631291. DOI: 10.3389/fimmu.2021.631291

55. Patel H, Pundkar A, Shrivastava S, Chandanwale R, Jaiswal AM. A Comprehensive Review on Platelet-Rich Plasma Activation: A Key Player in Accelerating Skin Wound Healing. *Cureus* 2023;15(11):e48943. DOI: 10.7759/cureus.48943

56. Murali A, Khan I, Tiwari S. Navigating the treatment landscape: Choosing between platelet-rich plasma (PRP) and hyaluronic acid (HA) for knee osteoarthritis management - A narrative review. *J Orthop Rep* 2023;3(1):100248. DOI: 10.1016/j.jo-rep.2023.100248

57. Singh CV, Jain S. The Role of Platelet-Rich Plasma in the Management of Sensorineural Hearing Loss: Current Evidence and Emerging Trends. *Cureus* 2024;16(9):e68646. DOI: 10.7759/cureus.68646

58. Halper J. Narrative Review and Guide: State of the Art and Emerging Opportunities of Bioprinting in tissue regeneration and Medical Instrumentation. *Bioengineering* 2025;12(1):71. DOI: 10.3390/bioengineering12010071

59. Mirshafiei M, Rashedi H, Yazdian F, Rahdar A, Baino F. Advancements in tissue and organ 3D bioprinting: Current techniques, applications, and future perspectives. *Mater Des* 2024;240:112853. DOI: 10.1016/j.matdes.2024.112853

60. El-Kadiy AE, Rafei M, Shammaa R. Cell Therapy: Types, Regulation, and Clinical Benefits. *Front Med* 2021;8:756029. DOI: 10.3389/fmed.2021.756029

61. Cole BJ, Seroyer ST, Filardo G, Bajaj S, Fortier LA. Platelet-rich plasma: where are we now and where are we going?. *Sports Health* 2010;2(3):203-10. DOI: 10.1177/1941738110366385

62. Liang K. Tissue Bioprinting: Promise and Challenges. *Bioengineering (Basel)* 2023;10(12):1400. DOI: 10.3390/bioengineering10121400

63. Schneider N, Sinnott M, Patel N, Joseph R. The Use of Platelet-Rich Plasma and Stem Cell Injections in Musculoskeletal Injuries. *Cureus* 2024;16(5):e59970. DOI: 10.7759/cureus.59970

64. Qian Y, Han Q, Chen W, Song J, Zhao X, Ouyang Y, et al. Platelet-Rich Plasma Derived Growth Factors Contribute to Stem Cell Differentiation in Musculoskeletal Regeneration. *Front Chem* 2017;5:89. DOI: 10.3389/fchem.2017.00089

65. Ntege EH, Sunami H, Shimizu Y. Advances in regenerative therapy: A review of the literature and future directions. *Regen Ther* 2020;14:136-53. DOI: 10.1016/j.reth.2020.01.004

66. Kleiderman E, Boily A, Hasilo C, Knoppers BM. Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials. *Stem Cell Res Ther* 2018;9(1):307. DOI: 10.1186/s13287-018-1055-2

67. Roca JB, Vaishnav P, Morgan M, Mendonça J, Fuchs E. When risks cannot be seen: Regulating uncertainty in emerging technologies. *Res Policy* 2017;46(7):1215-33. DOI: 10.1016/j.respol.2017.05.010

68. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther* 2019;10(1):68. DOI: 10.1186/s13287-019-1165-5
69. Kandi V, Vadakedath S. Clinical Trials and Clinical Research: A Comprehensive Review. *Cureus* 2023;15(2):e35077. DOI: 10.7759/cureus.35077
70. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and Safety Issues of Stem Cell-Based Therapy. *Int J Med Sci* 2018;15(1):36-45. DOI: 10.7150/ijms.21666
71. Goyal Y. The Moral Implications of Genetic Engineering. *Int J Adv Res* 2023;11(08):1094-8. DOI: 10.21474/ijar01/17495
72. Beheshtizadeh N, Gharibshahian M, Pazhouhnia Z, Rostami M, Zangi AR, Maleki R, et al. Commercialization and regulation of regenerative medicine products: Promises, advances and challenges. *Biomed Pharmacother* 2022;153:113431. DOI: 10.1016/j.biopha.2022.113431
73. Devi K, Joga R, Srivastava S, Nagpal K, Dhamija I, Grover P, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. *Eur J Pharm Biopharm* 2024;201:114361. DOI: 10.1016/j.ejpb.2024.114361
74. Chiticaru EA, Ioniță M. Commercially available bioinks and state-of-the-art lab-made formulations for bone tissue engineering: a comprehensive review. *Mater Today Bio* 2024;29:101341. DOI: 10.1016/j.mtbio.2024.101341
75. Ansori AN, Antonius Y, Susilo RJ, Hayaza S, Kharisma VD, Parikesit AA, et al. Application of CRISPR-Cas9 genome editing technology in various fields: A review. *Narra J* 2023;3(2):e184. DOI: 10.52225/narra.v3i2.184
76. Farag VE, Devey EA, Leong KW. The Interface of Gene Editing with Regenerative Medicine. *Engineering* 2024. DOI: 10.1016/j.eng.2024.10.019
77. Wang H, Yu H, Zhou X, Zhang J, Zhou H, Hao H, et al. An Overview of Extracellular Matrix-Based Bioinks for 3D Bioprinting. *Front Bioeng Biotechnol* 2022;10:905438. DOI: 10.3389/fbioe.2022.905438
78. Gungor-Ozkerim PS, Inci I, Zhang YS, Khademhosseini A, Dokmeci MR. Bioinks for 3D bioprinting: an overview. *Biomater Sci* 2018;6(5):915-946. DOI: 10.1039/c7bm00765e
79. Zhang Z, Zhou X, Fang Y, Xiong Z, Zhang T. AI-driven 3D bioprinting for regenerative medicine: From bench to bedside. *Bioact Mater* 2024;45:201-30. DOI: 10.1016/j.bioactmat.2024.11.021
80. Zhang S, Chen X, Shan M, Hao Z, Zhang X, Meng L, et al. Convergence of 3D bioprinting and nanotechnology in tissue engineering scaffolds. *Biomimetics* 2023;8(1):94. DOI: 10.3390/biomimetics8010094
81. Hasan A, Morshed M, Memic A, Hassan S, Webster TJ, Marei HE. Nanoparticles in tissue engineering: applications, challenges and prospects. *Int J Nanomedicine* 2018;13:5637-55. DOI: 10.2147/IJN.S153758
82. Alzoubi L, Aljabali AA, Tambuwala MM. Empowering Precision Medicine: The impact of 3D printing on personalized Therapeutic. *AAPS PharmSciTech* 2023;24(8):228. DOI: 10.1208/s12249-023-02682-w